Mark J. Ahn, Ph.D. is a Principal at Pukana Partners, Ltd. since 2009. Pukana is a strategic life sciences consulting company which focuses on providing thoughtful analysis, real-world solutions, and innovative strategies to accelerate value creation for biotechnology companies. Areas of engagement include: translating technology platforms into specific commercial opportunities; conducting industry, sector, and competitor analysis to support product development, portfolio planning, and competitive profiling; business strategic planning for senior management, Boards, and investor due diligence; and developing business development strategies to accelerate value creation. Pukana has been an integral part in many successful start up and multinational businesses and organizations in this field.
Most recently, he served as President & Chief Executive Officer, and Director of Galena Biopharma. Previously, he served as Chair, Science & Technology Management, Victoria University at Wellington, New Zealand. Dr. Ahn was also founder, President, and Chief Executive Officer of Hana Biosciences (acquired by Spectrum Pharmaceuticals). He also served as Vice President, Hematology and corporate officer at Genentech, Inc., as well as held positions of increasing responsibility at Amgen and Bristol-Myers Squibb Company; and served in the US Army.
Dr. Ahn also serves on public and venture capital-backed Board of Directors and Scientific Advisory Board. Dr. Ahn is the author of over 50 peer reviewed journal articles and books. Dr. Ahn received a BA and MBA from Chaminade University; and MA from Victoria University. He was a graduate fellow in Economics at Essex University, and obtained a Ph.D. from the University of South Australia. Dr. Ahn is a Henry Crown Fellow at the Aspen Institute.